These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 30541745)
1. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia. Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745 [TBL] [Abstract][Full Text] [Related]
2. EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX-351) for the Treatment of Adults with Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia-Related Changes. Tzogani K; Penttilä K; Lapveteläinen T; Hemmings R; Koenig J; Freire J; Márcia S; Cole S; Coppola P; Flores B; Barbachano Y; Roige SD; Pignatti F Oncologist; 2020 Sep; 25(9):e1414-e1420. PubMed ID: 32282100 [TBL] [Abstract][Full Text] [Related]
3. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes. Kim M; Williams S Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662 [TBL] [Abstract][Full Text] [Related]
4. CPX-351 (vyxeos) in AML. Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736 [TBL] [Abstract][Full Text] [Related]
5. Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia. Blair HA Drugs; 2018 Dec; 78(18):1903-1910. PubMed ID: 30511323 [TBL] [Abstract][Full Text] [Related]
6. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826 [TBL] [Abstract][Full Text] [Related]
7. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML. Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819 [TBL] [Abstract][Full Text] [Related]
8. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia. Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y; Int J Hematol; 2024 Jun; 119(6):647-659. PubMed ID: 38532078 [TBL] [Abstract][Full Text] [Related]
9. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail. Maakaron JE; Mims AS Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994 [TBL] [Abstract][Full Text] [Related]
10. Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. Chen EC; Fathi AT; Brunner AM Onco Targets Ther; 2018; 11():3425-3434. PubMed ID: 29928134 [TBL] [Abstract][Full Text] [Related]
11. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet JE; Uy GL; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Faderl S; Cortes JE Lancet Haematol; 2021 Jul; 8(7):e481-e491. PubMed ID: 34171279 [TBL] [Abstract][Full Text] [Related]
12. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia. Talati C; Lancet JE Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418 [TBL] [Abstract][Full Text] [Related]
13. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784 [TBL] [Abstract][Full Text] [Related]
14. Outpatient administration of liposomal daunorubicin and cytarabine (Vyxeos) in patients with secondary acute myeloid leukemia. Kasner MT Clin Adv Hematol Oncol; 2019 Nov; 17(11):604-606. PubMed ID: 31851160 [No Abstract] [Full Text] [Related]
15. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924 [TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088 [TBL] [Abstract][Full Text] [Related]
17. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Mayer LD; Tardi P; Louie AC Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803 [TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies. Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230 [TBL] [Abstract][Full Text] [Related]
19. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541 [TBL] [Abstract][Full Text] [Related]
20. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cortes JE; Goldberg SL; Feldman EJ; Rizzeri DA; Hogge DE; Larson M; Pigneux A; Recher C; Schiller G; Warzocha K; Kantarjian H; Louie AC; Kolitz JE Cancer; 2015 Jan; 121(2):234-42. PubMed ID: 25223583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]